secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001437749-25-032289
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia enrolls first patient at Wisconsin in Phase 3 CardiAMP HF II trial
----------------------------------------------------------------------------

- First patient enrolled at University of Wisconsin School of Medicine and Public Health in Phase 3 CardiAMP HF II trial.
- Trial is 250-patient randomized placebo-controlled study for ischemic HFrEF patients with elevated NTproBNP.
- Dr. Amish Raval serves as national co-principal investigator; UW is a prestigious cardiology center.
- Therapy uses autologous cells; cell population analysis defines doses; Helix system includes Morph DNA steerable platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774925032289/0001437749-25-032289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774925032289/bcda20251030_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-032289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer